MX347801B - Composicion farmaceutica para administracion por via oral para uso para la prevencion y/o el tratamiento de una enfermedad cardiovascular. - Google Patents

Composicion farmaceutica para administracion por via oral para uso para la prevencion y/o el tratamiento de una enfermedad cardiovascular.

Info

Publication number
MX347801B
MX347801B MX2015015753A MX2015015753A MX347801B MX 347801 B MX347801 B MX 347801B MX 2015015753 A MX2015015753 A MX 2015015753A MX 2015015753 A MX2015015753 A MX 2015015753A MX 347801 B MX347801 B MX 347801B
Authority
MX
Mexico
Prior art keywords
treatment
cardiovascular diseases
oral formulation
statin
acetylsalicylic acid
Prior art date
Application number
MX2015015753A
Other languages
English (en)
Other versions
MX2015015753A (es
Inventor
Martin Sanz Pablo
Urbano Hurtado Javier
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX347801(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of MX2015015753A publication Critical patent/MX2015015753A/es
Publication of MX347801B publication Critical patent/MX347801B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que incluye un inhibidor de la HMG-CoA reductasa, en particular, una estatina y ácido acetilsalicílico de manera que se minimiza la interacción del ácido acetilsalicílico con la estatina, para la prevención o el tratamiento de enfermedades cardiovasculares.
MX2015015753A 2013-06-06 2014-06-05 Composicion farmaceutica para administracion por via oral para uso para la prevencion y/o el tratamiento de una enfermedad cardiovascular. MX347801B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13170909.9A EP2810644A1 (en) 2013-06-06 2013-06-06 Oral formulation for the treatment of cardiovascular diseases
PCT/EP2014/061735 WO2014195421A1 (en) 2013-06-06 2014-06-05 Oral formulation for the treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
MX2015015753A MX2015015753A (es) 2016-08-03
MX347801B true MX347801B (es) 2017-05-15

Family

ID=48569993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015753A MX347801B (es) 2013-06-06 2014-06-05 Composicion farmaceutica para administracion por via oral para uso para la prevencion y/o el tratamiento de una enfermedad cardiovascular.

Country Status (42)

Country Link
US (1) US10617699B2 (es)
EP (3) EP2810644A1 (es)
JP (1) JP6151854B2 (es)
KR (1) KR101839665B1 (es)
CN (2) CN104224804A (es)
AP (1) AP2015008882A0 (es)
AR (1) AR096350A1 (es)
AU (1) AU2014276883B2 (es)
BR (1) BR112015030350B1 (es)
CA (1) CA2912350C (es)
CL (1) CL2015003561A1 (es)
CR (1) CR20150635A (es)
CU (1) CU24326B1 (es)
CY (1) CY1118766T1 (es)
DK (1) DK2986281T3 (es)
DO (1) DOP2015000296A (es)
EA (1) EA028969B1 (es)
EC (1) ECSP15050273A (es)
ES (1) ES2620078T3 (es)
GE (1) GEP201706743B (es)
HK (1) HK1204562A1 (es)
HU (1) HUE033458T2 (es)
IL (1) IL242569B (es)
MA (1) MA38699B1 (es)
MD (1) MD4475C1 (es)
MX (1) MX347801B (es)
MY (1) MY181272A (es)
NI (1) NI201500171A (es)
NZ (1) NZ714707A (es)
PE (1) PE20160051A1 (es)
PH (1) PH12015502706A1 (es)
PL (1) PL2986281T3 (es)
PT (1) PT2986281T (es)
RS (1) RS55786B1 (es)
SA (1) SA515370243B1 (es)
SG (1) SG11201509353QA (es)
SI (1) SI2986281T1 (es)
TN (1) TN2015000501A1 (es)
TW (1) TWI630928B (es)
UA (1) UA113806C2 (es)
WO (1) WO2014195421A1 (es)
ZA (1) ZA201508452B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170137101A (ko) * 2015-04-16 2017-12-12 노파르티스 아게 리보시클립 정제
CN111135149B (zh) * 2018-11-04 2021-05-11 张家港市中医医院 一种瑞舒伐他汀钙片及其制备方法
CN110693929A (zh) * 2019-09-09 2020-01-17 安徽中医药大学 复方药物组份在治疗脑梗死恢复期中的应用
PL4299063T3 (pl) 2022-06-30 2024-06-10 Ferrer Internacional, S.A. Kapsułki doustne zawierające tabletki atorwastatyny wykazujące odpowiedni profil rozpuszczania i biodostępność

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
WO1984002131A1 (en) 1982-11-22 1984-06-07 Sandoz Ag Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
WO1997038694A1 (en) 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
KR20030025903A (ko) 2000-02-10 2003-03-29 비피에스아이 홀딩스, 인코포레이션. 아크릴 장용 코팅 조성물
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20040115265A1 (en) 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
WO2004080488A2 (de) 2003-03-10 2004-09-23 Bayer Healthcare Ag Kombinationspräparate von acetylsalicylsäure mit einem hmg-coa-reduktase
US20050026992A1 (en) * 2003-07-28 2005-02-03 Sasmal Badal Kumar Treatment and prevention of cardiovascular events
ES2395724T3 (es) 2003-08-20 2013-02-14 Shionogi & Co., Ltd. Nueva composición de recubrimiento
BRPI0417017A (pt) 2003-11-26 2007-02-21 Novartis Ag compostos orgánicos
US20090098201A1 (en) * 2004-06-28 2009-04-16 Bio Intellectual Property Services (Bio Ips) Llc Composition and Method for Treatment and Prevention of Atherosclerosis
EP1856032A1 (en) 2005-03-11 2007-11-21 Speedel Experimenta AG Heterocyclic-substituted alkanamides useful as renin inhibitors
US20070009591A1 (en) 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20070116756A1 (en) 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US7427414B2 (en) 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
CN101176725A (zh) * 2006-07-14 2008-05-14 兰贝克赛实验室有限公司 辛伐他汀和阿司匹林的稳定剂型
SI2120878T1 (sl) * 2007-02-09 2014-12-31 Alphapharm Pty Ltd Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah
WO2009022821A2 (en) 2007-08-13 2009-02-19 Hanall Pharmaceutical Company. Ltd Combination preparation comprising inhibitor of hmg-coa reductase and aspirin and method for manufacturing the same
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
DK2273985T3 (en) * 2008-03-28 2016-04-25 Ferrer Int Capsule for the prevention of cardiovascular diseases
ES2690741T3 (es) * 2009-02-11 2018-11-22 Cadila Pharmaceuticals Ltd. Composición farmacéutica estable para la aterosclerosis
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
JP2013510145A (ja) 2009-11-09 2013-03-21 メディヴィル・アクチエボラーグ １，３−オキサゾリジン化合物およびレニン阻害剤としてのそれらの使用方法
KR101193493B1 (ko) * 2010-02-02 2012-10-22 한미사이언스 주식회사 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 ＨＭＧ?ＣｏＡ 환원효소 억제제를 포함하는 복합제제
CN102049049A (zh) * 2010-11-27 2011-05-11 王定豪 包含阿司匹林盐和他汀类药物的药物组合物

Also Published As

Publication number Publication date
KR101839665B1 (ko) 2018-03-16
ES2620078T3 (es) 2017-06-27
NZ714707A (en) 2019-04-26
CU20150173A7 (es) 2016-06-29
AR096350A1 (es) 2015-12-23
HK1204562A1 (en) 2015-11-27
CU24326B1 (es) 2018-03-13
ZA201508452B (en) 2017-02-22
SA515370243B1 (ar) 2016-09-19
PT2986281T (pt) 2017-03-29
MD4475B1 (ro) 2017-04-30
PH12015502706B1 (en) 2016-03-14
AU2014276883B2 (en) 2017-04-20
HUE033458T2 (en) 2017-12-28
CA2912350A1 (en) 2014-12-11
CY1118766T1 (el) 2017-07-12
EP2810644A1 (en) 2014-12-10
RS55786B1 (sr) 2017-07-31
MD20160001A2 (ro) 2016-05-31
TWI630928B (zh) 2018-08-01
KR20160014622A (ko) 2016-02-11
US10617699B2 (en) 2020-04-14
DK2986281T3 (en) 2017-04-03
EP3175849A1 (en) 2017-06-07
AU2014276883A1 (en) 2015-11-26
CN113143888A (zh) 2021-07-23
BR112015030350B1 (pt) 2022-11-29
MA38699B1 (fr) 2017-09-29
ECSP15050273A (es) 2017-07-31
SG11201509353QA (en) 2015-12-30
DOP2015000296A (es) 2016-12-30
JP6151854B2 (ja) 2017-06-21
BR112015030350A2 (pt) 2017-07-25
MD4475C1 (ro) 2017-11-30
TN2015000501A1 (en) 2017-04-06
NI201500171A (es) 2019-05-07
PH12015502706A1 (en) 2016-03-14
MY181272A (en) 2020-12-21
JP2016520135A (ja) 2016-07-11
EP2986281A1 (en) 2016-02-24
MA38699A1 (fr) 2017-01-31
SI2986281T1 (sl) 2017-07-31
TW201536357A (zh) 2015-10-01
WO2014195421A1 (en) 2014-12-11
US20160106763A1 (en) 2016-04-21
GEP201706743B (en) 2017-09-25
EP2986281B1 (en) 2016-12-21
AP2015008882A0 (en) 2015-11-30
CN104224804A (zh) 2014-12-24
IL242569B (en) 2018-12-31
PL2986281T3 (pl) 2017-06-30
MX2015015753A (es) 2016-08-03
CR20150635A (es) 2016-06-10
EA201600012A1 (ru) 2016-07-29
EA028969B1 (ru) 2018-01-31
CA2912350C (en) 2017-04-04
UA113806C2 (xx) 2017-03-10
PE20160051A1 (es) 2016-01-25
CL2015003561A1 (es) 2016-06-10

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
WO2014062720A3 (en) Methods of treating cancer
MX2012003555A (es) Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
UA118177C2 (uk) Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну
IN2012DE00912A (es)
TN2013000239A1 (en) New form of administration of enkephalinase inhibitor
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
PH12015502706B1 (en) Oral formulation for the treatment of cardiovascular diseases
MA40590A (fr) Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de protéine de transfert d'ester de cholestéryle et des inhibiteurs de hmg-coa réductase
MX2015013755A (es) Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis.
MX2015007945A (es) Usos y métodos para el tratamiento de enfermedades o afecciones hepáticas.
SG10202000597UA (en) PHARMACEUTICAL COMPOSITION COMPRISING AN HMG-CoA REDUCTASE INHIBITOR AND AN ACE INHIBITOR
ES2524645B1 (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
MX2012013052A (es) Asociacion de inhibidores de la xantina oxidasa y la instantina y su uso.
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز
UA92638U (ru) Способ профилактики возникновения первичных кардиальных конечных точек у больных нестабильной стенокардией с коморбидной артериальной гипертензией
MX2012006194A (es) Composiciones analgesicas que comprenden quercetina mas ketorolaco.
UA91070U (uk) Спосіб профілактики та корекції запальних захворювань на донозологічному рівні
UA59396U (ru) Применение композиций нестероидных противовоспалительных средств с кофеином как препаратов с антиэкссудативной активностью

Legal Events

Date Code Title Description
FG Grant or registration